Published: 2019-09-26

Clinical and microbiological profile in intra-abdominal infection

Chaithanya J., Ashwini R. K., Rajagopalan S.


Background: Intra-abdominal infections (IAIs) are different from other infections in a surgical patient. One important aspect is the microbiological analyses, especially in the era of broad spread of resistant microorganisms. The study was designed to describe the clinical and microbiological profiles of IAI.

Methods: A prospective study was conducted for a period of 1 year (December 2016 to November 2017) in Rajarajeswari Medical College and Hospital, Bangalore. Patients admitted and operated for acute abdomen/ IAI were included in this study and were analyzed.

Results: In 1 year period a total of 112 patients with IAI were assessed. A total of 5 types of micro-organisms were cultured. All the cultures were polymicrobial with aerobic organisms pre-dominantly gram negative bacilli (E.coli). The most common site was appendix. E. coli in this study showed 100.0% susceptibility to imipenem, 86% to meropenem and 77.6% to amoxi-clavulanate.

Conclusions: The most common site of IAIs was appendix (50%). E. coli (52%) is the most common organism isolated. 


Intra-abdominal infections, Empirical antibiotics, Microorganisms, Sensitivity

Full Text:



Sartelli M, Catena F, Ansaloni L, Lazzareschi DV, Taviloglu K, Van Goor H, et al. Complicated intra-abdominal infections observational European study (CIAO study). World J Emerg Surg. 2011;6(1):40.

Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect Dis. 2010;50(2):133-64.

Jean SS, Ko WC, Xie Y, Pawar V, Zhang D, Prajapati G, et al. Clinical characteristics of patients with community acquired complicated intra-abdominal infections: a prospective, multicentre, observational study. Int J Antimicrob Agents. 2014;44:222-8.

Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective observational EBIIA study. J Antimicrob Chemother. 2009;63:785–94.

Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, et al. The microbiology of postoperative peritonitis. Clin Infect Dis. 2001;33:1513–9.

Sotto A, Lefrant JY, Fabbro-Peray P, Muller L, Tafuri J, Navarro F, et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother. 2002;50:569–76.

Paterson DL, Rossi F, Baquero F, Hsueh PR, Woods GL, Satishchandran V, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 study for monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother. 2005;55:965–73.

Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother. 2006;58:205–10.

Baquero F, Hsueh PR, Paterson DL, Rossi F, Bochicchio GV, Gallagher G, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt). 2009;10:99-104.

Seguin P, Laviolle B, Chanavaz C, Donnio P-Y, Gautier- Lerestif AL, Campion JP, et al. Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect. 2006;12:980–5.

Lugito NP, Kurniawan A, Cucunawangsih et al. Clinical characteristics and microbiological profiles of community: Acquired Intra-Abdominal Infections. Indo J Gastro Hep Dig Endo. 2014;15(1):20-4.

Blot S, Waele JJD, Vogelaers D. Essentials for selecting therapy for intra-abdominal infections. Drugs 2012;72:e17-32.

de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PHJ. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection. 2009;37:522-7.

Ibrahim ME, Bilal NE, Hamid M. Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan. Afr Health Sci. 2012;12:368-75.

Drago L, Nicola L, Mattina R, Vecchi ED. In vitro lselection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations. BMC Microbiol. 2010;10:119.

Chenia, HY, Pillay B, Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother. 2006;58:1274-8.

Ouyang W, Xue H, Chen Y, Gao W, Li X, Wei J, et al. Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6 year epidemiological study in southern China. Int J Antimicrob Agents. 2016;47(3):210–6.

Shree N, Arora BS, Mohil RS, Kasana D, Biswal I. Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: Current experience in a teaching hospital. Indian J Pathol Microbiol. 2013;56:388-92.